Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures
Other News
Provisio Medical Announces Presentation at The Amputation Prevention Symposium (AMP) 2024 Conference
SAN DIEGO, Aug. 12, 2024 /PRNewswire/ — Provisio Medical, Inc., pioneers of Sonic Lumen Tomography™ (SLT) technology to provide real time blood vessel measurements during vascular interventions, today announced a key presentation featuring the Provisio™ SLT IVUS™ System during the annual…
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure
FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association (NYHA) functional class
Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma
– 2nd quarter conference call to be held Tuesday, August 13th, at 8:30 a.m. ET –
Acutus Medical Reports Second Quarter and Year-To-Date 2024 Financial Results
CARLSBAD, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the second quarter and year-to-date of 2024.
Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System
August 08, 2024 08:00 AM Eastern Daylight Time MIAMI–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced treatment of the first two patients in the first-in-human feasibility study using its novel Cardiac Surgery […]
SandboxAQ Collaborates with Mayo Clinic on Novel Cardiac Diagnostics
Clinical research study at leading U.S. hospital will further validate the efficacy of advanced, AI-powered magnetocardiography for transformative cardiac diagnostics PALO ALTO, Calif., Aug. 8, 2024 /PRNewswire/ — SandboxAQ today announced a technology collaboration with Mayo Clinic to…
LSU Athletics Becomes First College Sports Program to Use AI-Enabled Digital Stethoscopes From Eko Health to Care for Student-Athletes
Eko Health outfits LSU Athletic Sports Medicine team with CORE 500 digital stethoscopes and AI algorithms for the enhanced detection of cardiac conditions during athlete physical exams BATON ROUGE, La. & SAN FRANCISCO, Aug. 8, 2024 /PRNewswire/ — Eko Health, a pioneer in applying…
Silk Road Medical Reports Second Quarter 2024 Financial Results
SUNNYVALE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2024.
CroíValve Announces $16 Million Equity Financing to Fund US Early Feasibility Study of Novel Transcatheter Tricuspid Device
August 07, 2024 08:00 AM Eastern Daylight Time DUBLIN–(BUSINESS WIRE)–CroíValve, a pioneering medical device company focused on the development of a novel transcatheter device for the treatment of tricuspid regurgitation, announced today the closing of $16 million Series B financing. The round, led by the MedTech & Irrus Syndicates, included […]



